Bipolar disorder （BD） is a severe chronic mental disease with complex clinical manifestations and a high disability rate， and it is frequently comorbid with immune diseases. The pathogenic mechanism of the disease remains unclear， but current studies support the hypothesis that inflammatory responses and immunoregulatory disorders may play key roles in the pathogenesis of BD. At present， progress has been made in studies regarding adjuvant treatment of BD with anti-inflammatory and immunoregulatory drugs. Traditional anti-inflammatory drugs such as non-steroidal anti-inflammatory drugs and minocycline showed inconsistent therapeutic effects； there were more evidences for immunoregulatory drugs such as N-acetylcysteine and pioglitazone to be effective in improving depressive symptoms； microecological agents， tumor necrosis factor-α inhibitors， and interleukin-6 antagonists may have advantages in improving specific symptoms such as gastrointestinal reactions and fatigue. These treatment regimens may provide new options for resolving the dilemma of BD treatment. However， large-scale experiments are still needed in future studies to validate the efficacy， tolerability， and safety of the regimens. ［Journal of International Neurology and Neurosurgery, 2021, 48(1): 81-85］